APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neutropenia Biologic Drug Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neutropenia Biologic Drug Treatment Market Outlook and Growth Opportunities 2026

31 December 2025191 pages

Choose your research edition.

Industry ResearchNeutropenia Biologic Drug Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Neutropenia Biologic Drug Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Neutropenia Biologic Drug Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neutropenia Biologic Drug Treatment Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Neutropenia Biologic Drug Treatment Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Neutropenia Biologic Drug Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neutropenia Biologic Drug Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neutropenia Biologic Drug Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neutropenia Biologic Drug Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neutropenia Biologic Drug Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neutropenia Biologic Drug Treatment market include Kyowa Kirin, Teva Pharmaceutical Industries Ltd., Sanofi, Novartis, Pfizer, Baxter International, Amgen, Partner Therapeutics and Myelo Therapeutics GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Neutropenia Biologic Drug Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neutropenia Biologic Drug Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neutropenia Biologic Drug Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Neutropenia Biologic Drug Treatment market.

Neutropenia Biologic Drug Treatment Segment by Company

Kyowa Kirin

Teva Pharmaceutical Industries Ltd.

Sanofi

Novartis

Pfizer

Baxter International

Amgen

Partner Therapeutics

Myelo Therapeutics GmbH

Enzychem Lifesciences Corporation

Dong-A ST Co.,Ltd.

CVS Health

Cellerant Therapeutics

Neutropenia Biologic Drug Treatment Segment by Type

Filgrastim

Lenograstim

Pegfilgrastim

Sargramostim

Lipegfilgrastim

Neutropenia Biologic Drug Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Neutropenia Biologic Drug Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Neutropenia Biologic Drug Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Neutropenia Biologic Drug Treatment key companies, revenue, market share, and recent developments.

3. To split the Neutropenia Biologic Drug Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Neutropenia Biologic Drug Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neutropenia Biologic Drug Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Neutropenia Biologic Drug Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neutropenia Biologic Drug Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neutropenia Biologic Drug Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neutropenia Biologic Drug Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neutropenia Biologic Drug Treatment industry.

Chapter 3: Detailed analysis of Neutropenia Biologic Drug Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Neutropenia Biologic Drug Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Neutropenia Biologic Drug Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neutropenia Biologic Drug Treatment Industry Trends Table 2. Neutropenia Biologic Drug Treatment Industry Drivers Table 3. Neutropenia Biologic Drug Treatment Industry Opportunities and Challenges Table 4. Neutropenia Biologic Drug Treatment Industry Restraints Table 5. Global Neutropenia Biologic Drug Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neutropenia Biologic Drug Treatment Revenue Share by Company (2021-2026) Table 7. Global Neutropenia Biologic Drug Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Neutropenia Biologic Drug Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Neutropenia Biologic Drug Treatment Company, Product Type & Application Table 10. Global Neutropenia Biologic Drug Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Neutropenia Biologic Drug Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Filgrastim Table 15. Significant Companies of Lenograstim Table 16. Significant Companies of Pegfilgrastim Table 17. Significant Companies of Sargramostim Table 18. Significant Companies of Lipegfilgrastim Table 19. Global Neutropenia Biologic Drug Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Neutropenia Biologic Drug Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Neutropenia Biologic Drug Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Neutropenia Biologic Drug Treatment Sales Value Share by Type (2021-2026) Table 23. Global Neutropenia Biologic Drug Treatment Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital Pharmacies Table 25. Significant Companies of Online Pharmacies Table 26. Significant Companies of Retail Pharmacies Table 27. Global Neutropenia Biologic Drug Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Neutropenia Biologic Drug Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Neutropenia Biologic Drug Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Neutropenia Biologic Drug Treatment Sales Value Share by Application (2021-2026) Table 31. Global Neutropenia Biologic Drug Treatment Sales Value Share by Application (2027-2032) Table 32. Global Neutropenia Biologic Drug Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Neutropenia Biologic Drug Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Neutropenia Biologic Drug Treatment Sales Value Share by Region (2021-2026) Table 35. Global Neutropenia Biologic Drug Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Neutropenia Biologic Drug Treatment Sales Value Share by Region (2027-2032) Table 37. Global Neutropenia Biologic Drug Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Neutropenia Biologic Drug Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Neutropenia Biologic Drug Treatment Sales Value Market Share by Country (2021-2026) Table 40. Global Neutropenia Biologic Drug Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Neutropenia Biologic Drug Treatment Sales Value Market Share by Country (2027-2032) Table 42. Kyowa Kirin Company Information Table 43. Kyowa Kirin Business Overview Table 44. Kyowa Kirin Neutropenia Biologic Drug Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Kyowa Kirin Neutropenia Biologic Drug Treatment Product Portfolio Table 46. Kyowa Kirin Recent Development Table 47. Teva Pharmaceutical Industries Ltd. Company Information Table 48. Teva Pharmaceutical Industries Ltd. Business Overview Table 49. Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Product Portfolio Table 51. Teva Pharmaceutical Industries Ltd. Recent Development Table 52. Sanofi Company Information Table 53. Sanofi Business Overview Table 54. Sanofi Neutropenia Biologic Drug Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Sanofi Neutropenia Biologic Drug Treatment Product Portfolio Table 56. Sanofi Recent Development Table 57. Novartis Company Information Table 58. Novartis Business Overview Table 59. Novartis Neutropenia Biologic Drug Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Novartis Neutropenia Biologic Drug Treatment Product Portfolio Table 61. Novartis Recent Development Table 62. Pfizer Company Information Table 63. Pfizer Business Overview Table 64. Pfizer Neutropenia Biologic Drug Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Pfizer Neutropenia Biologic Drug Treatment Product Portfolio Table 66. Pfizer Recent Development Table 67. Baxter International Company Information Table 68. Baxter International Business Overview Table 69. Baxter International Neutropenia Biologic Drug Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Baxter International Neutropenia Biologic Drug Treatment Product Portfolio Table 71. Baxter International Recent Development Table 72. Amgen Company Information Table 73. Amgen Business Overview Table 74. Amgen Neutropenia Biologic Drug Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Amgen Neutropenia Biologic Drug Treatment Product Portfolio Table 76. Amgen Recent Development Table 77. Partner Therapeutics Company Information Table 78. Partner Therapeutics Business Overview Table 79. Partner Therapeutics Neutropenia Biologic Drug Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Partner Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio Table 81. Partner Therapeutics Recent Development Table 82. Myelo Therapeutics GmbH Company Information Table 83. Myelo Therapeutics GmbH Business Overview Table 84. Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Product Portfolio Table 86. Myelo Therapeutics GmbH Recent Development Table 87. Enzychem Lifesciences Corporation Company Information Table 88. Enzychem Lifesciences Corporation Business Overview Table 89. Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Product Portfolio Table 91. Enzychem Lifesciences Corporation Recent Development Table 92. Dong-A ST Co.,Ltd. Company Information Table 93. Dong-A ST Co.,Ltd. Business Overview Table 94. Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Product Portfolio Table 96. Dong-A ST Co.,Ltd. Recent Development Table 97. CVS Health Company Information Table 98. CVS Health Business Overview Table 99. CVS Health Neutropenia Biologic Drug Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. CVS Health Neutropenia Biologic Drug Treatment Product Portfolio Table 101. CVS Health Recent Development Table 102. Cellerant Therapeutics Company Information Table 103. Cellerant Therapeutics Business Overview Table 104. Cellerant Therapeutics Neutropenia Biologic Drug Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Cellerant Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio Table 106. Cellerant Therapeutics Recent Development Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Neutropenia Biologic Drug Treatment Product Image Figure 2. Global Neutropenia Biologic Drug Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Neutropenia Biologic Drug Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Filgrastim Image Figure 8. Lenograstim Image Figure 9. Pegfilgrastim Image Figure 10. Sargramostim Image Figure 11. Lipegfilgrastim Image Figure 12. Global Neutropenia Biologic Drug Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Neutropenia Biologic Drug Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Neutropenia Biologic Drug Treatment Sales Value Share by Type (2021-2032) Figure 15. Hospital Pharmacies Image Figure 16. Online Pharmacies Image Figure 17. Retail Pharmacies Image Figure 18. Global Neutropenia Biologic Drug Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Neutropenia Biologic Drug Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Neutropenia Biologic Drug Treatment Sales Value Share by Application (2021-2032) Figure 21. Global Neutropenia Biologic Drug Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Neutropenia Biologic Drug Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Neutropenia Biologic Drug Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. North America Neutropenia Biologic Drug Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Neutropenia Biologic Drug Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Neutropenia Biologic Drug Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Neutropenia Biologic Drug Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Neutropenia Biologic Drug Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Neutropenia Biologic Drug Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. South America Neutropenia Biologic Drug Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Neutropenia Biologic Drug Treatment Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Neutropenia Biologic Drug Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Filgrastim
  • Lenograstim
  • Pegfilgrastim
  • Sargramostim
  • Lipegfilgrastim
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Kyowa Kirin
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis
  • Pfizer
  • Baxter International
  • Amgen
  • Partner Therapeutics
  • Myelo Therapeutics GmbH
  • Enzychem Lifesciences Corporation
  • Dong-A ST Co.,Ltd.
  • CVS Health
  • Cellerant Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neutropenia Biologic Drug Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neutropenia Biologic Drug Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Neutropenia Biologic Drug Treatment Market Dynamics
  1. 2.1 Neutropenia Biologic Drug Treatment Industry Trends
  2. 2.2 Neutropenia Biologic Drug Treatment Industry Drivers
  3. 2.3 Neutropenia Biologic Drug Treatment Industry Opportunities and Challenges
  4. 2.4 Neutropenia Biologic Drug Treatment Industry Restraints
3 Neutropenia Biologic Drug Treatment Market by Company
  1. 3.1 Global Neutropenia Biologic Drug Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Neutropenia Biologic Drug Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Neutropenia Biologic Drug Treatment Company Ranking (2024-2026)
  4. 3.4 Global Neutropenia Biologic Drug Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Neutropenia Biologic Drug Treatment Company Product Type and Application
  6. 3.6 Global Neutropenia Biologic Drug Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Neutropenia Biologic Drug Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Neutropenia Biologic Drug Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Neutropenia Biologic Drug Treatment Market by Type
  1. 4.1 Neutropenia Biologic Drug Treatment Type Introduction
  2. 4.1.1 Filgrastim
  3. 4.1.2 Lenograstim
  4. 4.1.3 Pegfilgrastim
  5. 4.1.4 Sargramostim
  6. 4.1.5 Lipegfilgrastim
  7. 4.2 Global Neutropenia Biologic Drug Treatment Sales Value by Type
  8. 4.2.1 Global Neutropenia Biologic Drug Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Neutropenia Biologic Drug Treatment Sales Value by Type (2021-2032)
  10. 4.2.3 Global Neutropenia Biologic Drug Treatment Sales Value Share by Type (2021-2032)
5 Neutropenia Biologic Drug Treatment Market by Application
  1. 5.1 Neutropenia Biologic Drug Treatment Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Neutropenia Biologic Drug Treatment Sales Value by Application
  6. 5.2.1 Global Neutropenia Biologic Drug Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neutropenia Biologic Drug Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Neutropenia Biologic Drug Treatment Sales Value Share by Application (2021-2032)
6 Neutropenia Biologic Drug Treatment Regional Value Analysis
  1. 6.1 Global Neutropenia Biologic Drug Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neutropenia Biologic Drug Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Neutropenia Biologic Drug Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Neutropenia Biologic Drug Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neutropenia Biologic Drug Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Neutropenia Biologic Drug Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Neutropenia Biologic Drug Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Neutropenia Biologic Drug Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Neutropenia Biologic Drug Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Neutropenia Biologic Drug Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Neutropenia Biologic Drug Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Neutropenia Biologic Drug Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Neutropenia Biologic Drug Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Neutropenia Biologic Drug Treatment Sales Value Share by Country, 2025 VS 2032
7 Neutropenia Biologic Drug Treatment Country-level Value Analysis
  1. 7.1 Global Neutropenia Biologic Drug Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neutropenia Biologic Drug Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Neutropenia Biologic Drug Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Neutropenia Biologic Drug Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Neutropenia Biologic Drug Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Neutropenia Biologic Drug Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Neutropenia Biologic Drug Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Kyowa Kirin
  2. 8.1.1 Kyowa Kirin Company Information
  3. 8.1.2 Kyowa Kirin Business Overview
  4. 8.1.3 Kyowa Kirin Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Kyowa Kirin Neutropenia Biologic Drug Treatment Product Portfolio
  6. 8.1.5 Kyowa Kirin Recent Developments
  7. 8.2 Teva Pharmaceutical Industries Ltd.
  8. 8.2.1 Teva Pharmaceutical Industries Ltd. Company Information
  9. 8.2.2 Teva Pharmaceutical Industries Ltd. Business Overview
  10. 8.2.3 Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Product Portfolio
  12. 8.2.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Neutropenia Biologic Drug Treatment Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Neutropenia Biologic Drug Treatment Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Neutropenia Biologic Drug Treatment Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Baxter International
  32. 8.6.1 Baxter International Company Information
  33. 8.6.2 Baxter International Business Overview
  34. 8.6.3 Baxter International Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Baxter International Neutropenia Biologic Drug Treatment Product Portfolio
  36. 8.6.5 Baxter International Recent Developments
  37. 8.7 Amgen
  38. 8.7.1 Amgen Company Information
  39. 8.7.2 Amgen Business Overview
  40. 8.7.3 Amgen Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Amgen Neutropenia Biologic Drug Treatment Product Portfolio
  42. 8.7.5 Amgen Recent Developments
  43. 8.8 Partner Therapeutics
  44. 8.8.1 Partner Therapeutics Company Information
  45. 8.8.2 Partner Therapeutics Business Overview
  46. 8.8.3 Partner Therapeutics Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Partner Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio
  48. 8.8.5 Partner Therapeutics Recent Developments
  49. 8.9 Myelo Therapeutics GmbH
  50. 8.9.1 Myelo Therapeutics GmbH Company Information
  51. 8.9.2 Myelo Therapeutics GmbH Business Overview
  52. 8.9.3 Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Product Portfolio
  54. 8.9.5 Myelo Therapeutics GmbH Recent Developments
  55. 8.10 Enzychem Lifesciences Corporation
  56. 8.10.1 Enzychem Lifesciences Corporation Company Information
  57. 8.10.2 Enzychem Lifesciences Corporation Business Overview
  58. 8.10.3 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Product Portfolio
  60. 8.10.5 Enzychem Lifesciences Corporation Recent Developments
  61. 8.11 Dong-A ST Co.,Ltd.
  62. 8.11.1 Dong-A ST Co.,Ltd. Company Information
  63. 8.11.2 Dong-A ST Co.,Ltd. Business Overview
  64. 8.11.3 Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Product Portfolio
  66. 8.11.5 Dong-A ST Co.,Ltd. Recent Developments
  67. 8.12 CVS Health
  68. 8.12.1 CVS Health Company Information
  69. 8.12.2 CVS Health Business Overview
  70. 8.12.3 CVS Health Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 CVS Health Neutropenia Biologic Drug Treatment Product Portfolio
  72. 8.12.5 CVS Health Recent Developments
  73. 8.13 Cellerant Therapeutics
  74. 8.13.1 Cellerant Therapeutics Company Information
  75. 8.13.2 Cellerant Therapeutics Business Overview
  76. 8.13.3 Cellerant Therapeutics Neutropenia Biologic Drug Treatment Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Cellerant Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio
  78. 8.13.5 Cellerant Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst